Nothing Special   »   [go: up one dir, main page]

Congleton, 2006 - Google Patents

Yersinia pestis YopM and its interaction with penta-EF-hand-proteins

Congleton, 2006

Document ID
16268396747921355471
Author
Congleton Y
Publication year

External Links

Snippet

Yersinia pestis delivers the virulence protein YopM into the cytosol of host cells, where this protein goes to the nucleus by using a vesicular trafficking pathway. As a result, YopM possibly interacts with multiple proteins in the host cell. Preliminary data identified a …
Continue reading at search.proquest.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Similar Documents

Publication Publication Date Title
KR101653774B1 (en) Oligopeptidic compounds and uses thereof
Knodler et al. Salmonella type III effectors PipB and PipB2 are targeted to detergent‐resistant microdomains on internal host cell membranes
Jiménez-Soto et al. Helicobacter pylori type IV secretion apparatus exploits β1 integrin in a novel RGD-independent manner
ES2287020T3 (en) PROCEDURE AND COMPOSITIONS TO INHIBIT THE GROWTH OF NEOPLASSIC CELLS.
JP2010540611A (en) Methods of treating cancer using Notch pathway inhibitors
US20060111287A1 (en) Acetylated protein
Rhomberg et al. A translocated protein of Bartonella henselae interferes with endocytic uptake of individual bacteria and triggers uptake of large bacterial aggregates via the invasome
Florimond et al. BILBO1 is a scaffold protein of the flagellar pocket collar in the pathogen Trypanosoma brucei
CN105061580B (en) Polypeptide and pharmaceutical composition and application thereof
WO2021081032A1 (en) Compositions comprising modified smarcb1 and uses thereof
CN105764923A (en) Peptides inhibiting cold-inducible RNA binding protein activity
US20090215666A1 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
JP2004508045A5 (en)
JP2004508045A (en) Human and mouse targeting peptides identified by phage display
Cordes et al. Mediators of nuclear protein import target karyophilic proteins to pore complexes of cytoplasmic annulate lamellae
AU2012272550B2 (en) Prevention and treatment of acute inflammatory conditions
Congleton Yersinia pestis YopM and its interaction with penta-EF-hand-proteins
WO2006068822A1 (en) Notch receptor agonists and uses
JP2020128349A (en) Cancer metastasis-inhibiting agents and methods for selecting candidate substances of cancer metastasis-inhibiting agents
AU2012310086A1 (en) Antibodies directed against signal peptides, methods and uses thereof
Mhatre et al. The guinea pig cochlear AE2 anion exchanger: cDNA cloning and in situ localization within the cochlea
WO2003062272A1 (en) Novel strategy for modulating t cell activation which is based on regulating the cd3ε - nck interaction
KR101890289B1 (en) Compositions for the therapeutic use of a Armadillo repeat domain 2 associated sequence
Lee Carcinoembryonic antigen-related cellular adhesion molecule 1-dependent inhibition of T cell responses
US9422350B2 (en) Target of EGR1 (TOE1) polypeptides for inhibition of HIV